McKesson — May 7, 2026 release

Outlook: • Establishing fiscal 2027 Adjusted Earnings per Diluted Share guidance range of $43.80 to $44.60, which indicates 12% to 14% forecasted growth compared to the prior year. • Reaffirming long-term Adjusted Earnings per Diluted Share growth target of 13% to 16%. • The Company does not forecast GAAP earnings per diluted share 1 . "McKesson's fourth quarter results reflect the strength of our diversified portfolio and disciplined execution against our strategic priorities. Our Fiscal 2026 performance, headlined by 12% revenue growth and 18% adjusted EPS growth, exceeded our long-range growth targets and demonstrates our ability to consistently deliver growth and operating leverage across the enterprise," said Brian Tyler, chief executive officer. "We delivered significant progress - expanding specialty provider support, accelerating patient access through our scaled and integrated biopharma support services, and continuing to optimize our portfolio through the divestiture of Europe and the planned separation of our Medical-Surgical business. These accomplishments are a direct result of the talent and operational excellence of our employees, and I want to thank Team McKesson for their continued dedication throughout the year." "Looking ahead to fiscal 2027, we are well-positioned to build upon this momentum," said Mr. Tyler. "We remain committed to executing with discipline across the portfolio, investing in high-growth and high-margin area